Literature DB >> 25994569

FOXP4 modulates tumor growth and independently associates with miR-138 in non-small cell lung cancer cells.

Tian Yang1, Hong Li1, Asmitananda Thakur1, Tianjun Chen1, Jing Xue1, Dan Li1, Mingwei Chen2.   

Abstract

Family of forkhead box transcription factors, including forkhead box P4 (FOXP4), plays an important role in oncogenesis. The current study is to evaluate the role of FOXP4 in regulating human non-small cell lung cancer (NSCLC). Quantitative RT-PCR and Western blot were performed to evaluate the gene and protein expressions of FOXP4 in six NSCLC cell lines and 55 NSCLC patients. Lentivirus of small hairpin RNA (FOXP4-shRNA) was used to downregulate FOXP4 in NSCLC cell lines A549 and H1703 cells. Its effect on NSCLC growth, invasion, and cell cycle were evaluated by cell proliferation assay, migration assay, and cell cycle assay, respectively. Dual luciferase assay and Western blot were used to examine whether microRNA-138 (miR-138) was an upstream regulator of FOXP4. The dependence of FOXP4 on miR-138 associated signaling pathway was evaluated by ectopically overexpressing enhancer of zeste homolog 2 (EZH2), a known miR-138 target in NSCLC. FOXP4 was highly expressed in both NSCLC cell lines and NSCLC patients. FOXP4 downregulation by FOXP4-shRNA markedly reduced cancer cell growth and invasion, as well as induced cell cycle arrest in A549 and H1703 cells. MiR-138 was confirmed to be an upstream regulator of FOXP4 and directly regulated FOXP4 expression in A549 and H1703 cells. FOXP4 downregulation-mediated inhibition on cancer cell growth and invasion was independent on overexpressing EZH2, another direct target of miR-138 in NSCLC. Our data demonstrated that FOXP4 was a critical regulator in NSCLC and independently associated with miR-138 regulation.

Entities:  

Keywords:  Cancer growth; Cancer migration; EZH2; FOXP4; NSCLC; miR-138

Mesh:

Substances:

Year:  2015        PMID: 25994569     DOI: 10.1007/s13277-015-3498-8

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  16 in total

Review 1.  The emerging roles of forkhead box (Fox) proteins in cancer.

Authors:  Stephen S Myatt; Eric W-F Lam
Journal:  Nat Rev Cancer       Date:  2007-11       Impact factor: 60.716

Review 2.  Molecular targeted therapy in the treatment of advanced stage non-small cell lung cancer (NSCLC).

Authors:  Nesaretnam Barr Kumarakulasinghe; Nico van Zanwijk; Ross A Soo
Journal:  Respirology       Date:  2015-02-17       Impact factor: 6.424

Review 3.  Genomic profiling of small-cell lung cancer: the era of targeted therapies.

Authors:  Shigeki Umemura; Katsuya Tsuchihara; Koichi Goto
Journal:  Jpn J Clin Oncol       Date:  2015-02-10       Impact factor: 3.019

4.  Association of FOXP3 expression with non-small cell lung cancer.

Authors:  Fotinos-Ioannis D Dimitrakopoulos; Helen Papadaki; Anna G Antonacopoulou; Anastasia Kottorou; Andreas D Gotsis; Chrisoula Scopa; Haralabos P Kalofonos; Athanasia Mouzaki
Journal:  Anticancer Res       Date:  2011-05       Impact factor: 2.480

5.  MicroRNA-338-3p inhibits cell proliferation in hepatocellular carcinoma by target forkhead box P4 (FOXP4).

Authors:  Gang Wang; Yubei Sun; Yifu He; Chushu Ji; Bing Hu; Yuping Sun
Journal:  Int J Clin Exp Pathol       Date:  2015-01-01

6.  Expression of Foxp3 in non-small cell lung cancer patients is significantly higher in tumor tissues than in normal tissues, especially in tumors smaller than 30 mm.

Authors:  Yasunori Ishibashi; Shigebumi Tanaka; Kohei Tajima; Takeshi Yoshida; Hiroyuki Kuwano
Journal:  Oncol Rep       Date:  2006-05       Impact factor: 3.906

7.  Reduced expressions of Foxp1 and Rassf1a genes in lung adenocarcinomas induced by N-nitrosobis(2-hydroxypropyl)amine in rats.

Authors:  Kyoko Shimizu; Ayumi Kato; Daisei Hinotsume; Mayumi Shigemura; Madoka Hanaoka; Yozo Shimoichi; Kanya Honoki; Toshifumi Tsujiuchi
Journal:  Cancer Lett       Date:  2005-07-14       Impact factor: 8.679

8.  High expression of FoxP1 is associated with improved survival in patients with non-small cell lung cancer.

Authors:  Jian Feng; Xuesong Zhang; Huijun Zhu; Xudong Wang; Songshi Ni; Jianfei Huang
Journal:  Am J Clin Pathol       Date:  2012-08       Impact factor: 2.493

9.  FoxP4, a novel forkhead transcription factor.

Authors:  Andreas Teufel; Eric A Wong; Mahua Mukhopadhyay; Nasir Malik; Heiner Westphal
Journal:  Biochim Biophys Acta       Date:  2003-06-19

Review 10.  Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data.

Authors: 
Journal:  Lancet       Date:  2014-02-25       Impact factor: 79.321

View more
  18 in total

1.  Up-regulation of microRNA-491-5p suppresses cell proliferation and promotes apoptosis by targeting FOXP4 in human osteosarcoma.

Authors:  Zhixun Yin; Hongmei Ding; Erxing He; Jingchen Chen; Ming Li
Journal:  Cell Prolif       Date:  2016-10-05       Impact factor: 6.831

2.  TFEB-VEGFA (6p21.1) co-amplified renal cell carcinoma: a distinct entity with potential implications for clinical management.

Authors:  Sounak Gupta; Sarah H Johnson; George Vasmatzis; Binu Porath; Jeannette G Rustin; Priya Rao; Brian A Costello; Bradley C Leibovich; R Houston Thompson; John C Cheville; William R Sukov
Journal:  Mod Pathol       Date:  2017-03-24       Impact factor: 7.842

Review 3.  The functions, oncogenic roles, and clinical significance of circular RNAs in renal cell carcinoma.

Authors:  Hui Huang; Tao Chen; Fei Li; Dan Jin; Chuan Li; Yongbo Yang; Xuyang Liu; Dongmiao Wang; Jiehui Di
Journal:  Med Oncol       Date:  2022-05-15       Impact factor: 3.064

4.  Forkhead box N1 inhibits the progression of non-small cell lung cancer and serves as a tumor suppressor.

Authors:  Xiaojian Ji; Yan Ji; Wenqing Wang; Xinmei Xu
Journal:  Oncol Lett       Date:  2018-03-08       Impact factor: 2.967

Review 5.  MicroRNAs: The Link between the Metabolic Syndrome and Oncogenesis.

Authors:  Adriana Fodor; Andrada Luciana Lazar; Cristina Buchman; Brandusa Tiperciuc; Olga Hilda Orasan; Angela Cozma
Journal:  Int J Mol Sci       Date:  2021-06-13       Impact factor: 5.923

Review 6.  MicroRNAs as regulators and mediators of forkhead box transcription factors function in human cancers.

Authors:  Chen Li; Kai Zhang; Jing Chen; Longbang Chen; Rui Wang; Xiaoyuan Chu
Journal:  Oncotarget       Date:  2017-02-14

7.  Circular RNA circABCC4 as the ceRNA of miR-1182 facilitates prostate cancer progression by promoting FOXP4 expression.

Authors:  Changkun Huang; Huanghao Deng; Yinhuai Wang; Hongyi Jiang; Ran Xu; Xuan Zhu; Zhichao Huang; Xiaokun Zhao
Journal:  J Cell Mol Med       Date:  2019-07-03       Impact factor: 5.310

Review 8.  MicroRNAs as regulators of cisplatin-resistance in non-small cell lung carcinomas.

Authors:  Irina Fadejeva; Horst Olschewski; Andelko Hrzenjak
Journal:  Oncotarget       Date:  2017-12-05

9.  Genome-wide association study of subclinical interstitial lung disease in MESA.

Authors:  Ani Manichaikul; Xin-Qun Wang; Li Sun; Josée Dupuis; Alain C Borczuk; Jennifer N Nguyen; Ganesh Raghu; Eric A Hoffman; Suna Onengut-Gumuscu; Emily A Farber; Joel D Kaufman; Dan Rabinowitz; Karen D Hinckley Stukovsky; Steven M Kawut; Gary M Hunninghake; George R Washko; George T O'Connor; Stephen S Rich; R Graham Barr; David J Lederer
Journal:  Respir Res       Date:  2017-05-18

Review 10.  The Dominant Role of Forkhead Box Proteins in Cancer.

Authors:  Duc-Hiep Bach; Nguyen Phuoc Long; Thi-Thu-Trang Luu; Nguyen Hoang Anh; Sung Won Kwon; Sang Kook Lee
Journal:  Int J Mol Sci       Date:  2018-10-22       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.